Innovation Research

We're developing better more intelligent viral vectors to push science forward

 
 

Our approach to innovation is clear

 

1. Novel lentiviral and retroviral manufacturing technologies

Improving manufacturing yields and vector-specific performance

  • Engineered lentiviral and retroviral vector backbones for improved safety & efficacy

  • Novel suspension cell line development for lentiviral and retroviral GMP manufacturing

  • Developing a stable lentiviral packaging cell line

  • Novel media additives and transfection enhancers

 
 

2. Ligand-modified vectors

Physically engineered viral vectors to convey specific performance enhancing properties

  • Tissue specific tropism

  • Affinity purification and viral vector concentration

  • Transfection efficiency enhancement


3. Programmable intelligent vectors

Disruptive potential to establish new industry-standard viral vector platforms

  • Anti-oncogenic safety switches

  • Non-integrating lentiviral vectors for in vivo applications

  • Viral vectors with tissue-specific and cell-specific tropism and activity

 

When developing vectors, we always have de-risking in the back of our minds.
— DAVID DARLING, PhD, SENIOR PRINCIPLAL SCIENTIST, INNOVATION

 
 

We have several synergistic projects that include serum-free suspension cell lines for stable vector production.
— GLENDA DICKSON, PhD, PRINCIPAL SCIENTIST, INNOVATION